Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Darunavir (Prezista®) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of three years and at least 15 kg body weight. |
|||
|
|||
Medicine details |
|||
| Medicine name | darunavir (Prezista®) | ||
| Formulation | 75 mg, 150 mg, 300 mg, 600 mg and 800 mg film-coated tablet, 100 mg/ml oral suspension | ||
| Reference number | 2579 | ||
| Indication | Co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of 3 years and at least 15 kg body weight |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1815 | ||
| NMG meeting date | 13/05/2015 | ||
| AWMSG meeting date | 17/06/2015 | ||
| Ratification by Welsh Government | 15/07/2015 | ||
| Date of issue | 16/07/2015 | ||
| Date of last review | 11/04/2019 | ||